Current Headlines

  1. HUYA And Changzhou Center Link Arms In Drug Development
    8/22/2014

    HUYA Bioscience International, a China-based international drug development firm, and Changzhou Center for Biotech Development (CZCBD) announced a strategic collaboration to advance innovations from bio-pharmaceutical companies located in Changzhou that have the potential to meet pharmaceutical needs in the global arena.

  2. New Vaccine Puts Up Stronger Fight Against Both Tuberculosis And Leprosy
    8/22/2014

    Researchers at the University of California Los Angeles have prepared a new and improved variant of an existing vaccine, which is found to offer stronger protection against the two major infectious diseases, tuberculosis (TB) and leprosy. The study has been published in the journal Infection and Immunity.

  3. Amicus Therapeutics' Fabry Treatment Shows Positive Results In Phase 3 Trials
    8/22/2014

    Amicus Therapeutics has just announced the positive results from its second Phase 3 clinical trial of its new drug, Migalastat, to treat Fabry disease. Migalastat, Amicus' first main drug, is now closer to becoming the first oral treatment for patients with this potentially fatal genetic disorder.

  4. Researchers Show Involvement Of DNA Modifications in Alzheimer's Disease
    8/21/2014

    In a couple of recent breakthrough research reports, scientists have revealed how modifications to DNA are involved in Alzheimer's disease

  5. Expression Therapeutics, ABL Enter Collaboration For Hemophilia A Factor VIII Infusion Therapy Cell Line Development
    8/21/2014

    Expression Therapeutics, a biotechnology company which is developing therapies for hemophilia A, has just selected the Maryland-based biomedical contract research and manufacturing organization, ABL to support the cell line development studies for its novel Factor VIII infusion therapy for Hemophilia A.

  6. Pharming Group Acquires Rare Disease Candidates in TRM SASU Liquidation
    8/21/2014

    Dutch biotech company, Pharming Group announced a half million euro deal ($667,000), acquiring assets from the French company, Transgenic Rabbit Models (TRM) SASU, liquidation. This deal gives Pharming Group access to five recombinant human product candidates for the treatment of rare genetic disorders: Pompe’s disease, Fabry’s disease, Gaucher’s disease, and Hemophilia A and B.

  7. Glenmark Enters Oncology With Discovery of New Molecule
    8/21/2014

    Indian Pharma company, Glenmark has entered oncology with the discovery of GBR 1302, a potential antibody-based therapy for ovarian and breast cancers.

  8. BMS And Celgene Collaborate For Combination Cancer Treatment Study
    8/21/2014

    Bristol-Myers Squibb Company (BMS) and Celgene Corporation announced Wednesday that they are collaborating on a Phase I clinical study, which will determine the efficacy of a combination regimen of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, Opdivo (nivolumab) and Celgene’s nab technology-based chemotherapy Abraxane (paclitaxel protein-bound particles for injectable suspension) (albumin-bound). The collaborating parties will study multiple types of tumors, including HER-2 negative metastatic breast cancer, pancreatic cancer, and nonsmall cell lung cancer (NSCLC).

  9. Pfizer Files NDA For Palbociclib In Breast Cancer With FDA
    8/20/2014

    Pfizer announced that it has completed the filing of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for its investigational drug palbociclib for the treatment of postmenopausal, treatment-naive women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.

  10. Lilly, Boehringer Ingelheim Get Tentative FDA OK For Basaglar
    8/20/2014

    Eli Lilly together with its partner Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval to Basaglar (insulin glargine injection) indicated for the improvement of glycemic control in adult patients with Type 2 diabetes.